טוען...
Flow Cytometry Quality Requirements for Monitoring of Minimal Disease in Plasma Cell Myeloma
Current therapeutic approaches for plasma cell myeloma (PCM) attain an overall survival of more than 6 years for the majority of newly diagnosed patients. However, PFS and OS are the only accepted FDA clinical endpoints for demonstrating drug efficacy before they can be become frontline therapeutic...
שמור ב:
| הוצא לאור ב: | Cytometry B Clin Cytom |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5404813/ https://ncbi.nlm.nih.gov/pubmed/26201282 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cyto.b.21276 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|